BioSpace News Archive

New findings from MS PATHS show that treatment with TYSABRI ® (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus ® (ocrelizumab) Real-world data from VUMERITY ® (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability profile Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government’s R&D tax incentive program

Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-initiated study designed to assess caregivers’ perspectives on the long-term seizure- and non-seizure-related benefits of FINTEPLA®

GENOSYL® Delivery System, a novel tankless, cassette-based delivery system for Inhaled Nitric Oxide, can greatly facilitate the delivery of iNO during interhospital transport of newborns, according to a new publication in the Spring 2021 issue of the journal RT Magazine

Peptron, Inc. (“Peptron”, KOSDAQ: 087010), a South Korea-based biotech company, and Qilu Pharmaceutical (“Qilu”), a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines announced today that the companies have entered into an exclusive licensing agreement for the manufacturing,

Heska Corporation (NASDAQ: HSKA) (“Heska” or the “Company”), a leading provider of advanced veterinary diagnostic and specialty products, announces its 2021 Annual Meeting of Stockholders.

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on April 13, 2021, the company granted non-statutory stock options to purchase an aggregate of 7,450 shares of the company’s common stock to three newly-hired employees.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has exercised its right of first refusal to expand the lease for its “Factory of the Future” manufacturing facility near Portland, Oregon.